Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REPRISE NGDS: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of LotuS™ ValvE With the Next Generation Delivery System

NCT02329496 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT02329496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02329496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REPRISE NGDS: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of LotuS™ ValvE With the Next Generation Delivery System
Lead sponsor
Boston Scientific Corporation
Phase
Not applicable
Overall status
Completed
Start date
December 3, 2014
Completion date
October 19, 2017
Enrollment
38 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

aortic stenosis